Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:34PM ET
2.70
Dollar change
+0.03
Percentage change
1.12
%
Index- P/E- EPS (ttm)-1.68 Insider Own3.93% Shs Outstand71.75M Perf Week6.72%
Market Cap193.73M Forward P/E- EPS next Y-1.42 Insider Trans0.00% Shs Float68.93M Perf Month5.88%
Income-85.02M PEG- EPS next Q-0.08 Inst Own13.72% Short Float0.99% Perf Quarter-22.19%
Sales16.50M P/S11.74 EPS this Y57.66% Inst Trans-2.45% Short Ratio14.85 Perf Half Y68.75%
Book/sh1.37 P/B1.97 EPS next Y-43.45% ROA-29.36% Short Interest0.68M Perf Year32.68%
Cash/sh0.94 P/C2.88 EPS next 5Y- ROE-67.51% 52W Range0.96 - 3.77 Perf YTD-12.34%
Dividend Est.- P/FCF- EPS past 5Y3.50% ROI-52.10% 52W High-28.45% Beta3.11
Dividend TTM- Quick Ratio2.20 Sales past 5Y77.59% Gross Margin92.50% 52W Low180.44% ATR (14)0.16
Dividend Ex-Date- Current Ratio2.20 EPS Y/Y TTM26.81% Oper. Margin-512.25% RSI (14)54.77 Volatility6.81% 5.98%
Employees237 Debt/Eq1.32 Sales Y/Y TTM6.65% Profit Margin-515.39% Recom2.00 Target Price5.00
Option/ShortYes / Yes LT Debt/Eq1.14 EPS Q/Q49.69% Payout- Rel Volume0.97 Prev Close2.67
Sales Surprise-51.38% EPS Surprise25.84% Sales Q/Q-28.57% EarningsNov 06 AMC Avg Volume45.74K Price2.70
SMA206.28% SMA50-1.22% SMA20015.92% Trades Volume22,651 Change1.12%
Date Action Analyst Rating Change Price Target Change
Mar-17-23Initiated Bryan Garnier Buy $6
May-18-22Upgrade Robert W. Baird Neutral → Outperform $10
Jan-06-22Downgrade Wells Fargo Overweight → Equal Weight $39 → $16
Nov-30-21Initiated JMP Securities Mkt Outperform $20
Nov-08-21Downgrade William Blair Outperform → Mkt Perform
Oct-08-21Downgrade Robert W. Baird Outperform → Neutral $39 → $10
Apr-28-21Downgrade Guggenheim Buy → Neutral
Mar-16-21Upgrade Robert W. Baird Neutral → Outperform $23 → $39
Aug-19-20Upgrade Citigroup Neutral → Buy $15 → $32
May-12-20Initiated Robert W. Baird Outperform $20
Mar-04-24 04:30PM
Feb-02-24 04:30PM
Jan-16-24 04:30PM
Jan-08-24 04:30PM
Dec-22-23 04:30PM
04:30PM Loading…
Dec-01-23 04:30PM
Nov-17-23 04:30PM
Nov-15-23 02:30AM
Nov-06-23 04:30PM
Nov-03-23 04:30PM
Nov-02-23 04:30PM
Nov-01-23 04:30PM
08:13AM
08:02AM
03:00AM
04:30PM Loading…
Oct-31-23 04:30PM
Oct-24-23 04:30PM
Oct-12-23 04:30PM
Oct-03-23 04:30PM
09:55AM
Sep-27-23 04:30PM
Sep-05-23 04:30PM
Aug-07-23 04:30PM
Aug-03-23 04:30PM
Aug-01-23 04:30PM
Jul-27-23 04:30PM
Jul-12-23 04:30PM
Jun-28-23 04:30PM
Jun-13-23 04:30PM
Jun-09-23 04:30PM
04:30PM Loading…
Jun-05-23 04:30PM
May-31-23 04:50PM
May-17-23 04:30PM
May-12-23 01:30AM
May-11-23 10:20AM
May-10-23 04:30PM
May-04-23 04:30PM
May-02-23 04:35PM
Apr-27-23 04:30PM
Apr-24-23 04:30PM
Apr-17-23 02:00AM
Apr-12-23 04:30PM
Apr-11-23 04:30PM
Apr-04-23 04:30PM
Mar-15-23 05:02PM
Mar-14-23 05:00PM
Mar-08-23 04:45PM
Mar-06-23 04:30PM
Mar-01-23 04:30PM
Feb-09-23 04:30PM
Feb-07-23 07:01PM
Feb-03-23 09:33AM
12:48AM
Feb-02-23 04:01PM
Jan-30-23 07:10PM
Jan-20-23 04:30PM
Jan-17-23 07:10AM
Jan-09-23 04:30PM
Jan-04-23 05:08PM
Dec-29-22 04:30PM
Dec-28-22 04:30PM
Dec-22-22 04:30PM
Dec-16-22 04:30PM
Dec-13-22 01:47PM
07:30AM
Dec-01-22 04:40PM
Nov-10-22 09:05AM
02:48AM
Nov-08-22 04:30PM
Nov-04-22 12:31PM
Nov-03-22 04:36PM
04:05PM
Oct-27-22 04:37PM
Oct-11-22 04:30PM
Oct-10-22 04:30PM
Oct-05-22 09:45AM
Sep-28-22 04:23PM
Sep-19-22 04:30PM
Sep-01-22 04:44PM
Aug-22-22 04:30PM
Aug-05-22 12:13PM
Aug-04-22 04:30PM
Aug-01-22 04:30PM
Jul-28-22 04:30PM
Jul-20-22 07:53AM
Jun-30-22 05:19AM
Jun-28-22 04:36PM
04:08PM
Jun-27-22 09:39AM
Jun-08-22 04:30PM
May-23-22 04:35PM
May-20-22 07:35PM
May-16-22 08:15AM
May-12-22 04:31PM
May-10-22 04:43PM
May-05-22 04:40PM
04:14PM
Apr-28-22 08:00AM
Apr-27-22 12:51PM
02:44AM
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.